Are these 2 impressive ASX shares buys for 2022?

ELMO Software is one of the potential options for 2022.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The next year is almost here. There are some impressive ASX shares to consider for 2022 which experts have rated as buys.

Businesses which are growing quickly have the ability to achieve attractive compound growth over a number of years.

a woman stares ahead with a serious expression on her face while half of her face is covered by computer coding, indicative of artificial intelligence and machine learning technology.

Image source: Getty Images

Bubs Australia Ltd (ASX: BUB)

Bubs is a leading goat milk infant formula business, but the Bubs share price has dropped by 24% this year.

The business is rated as a buy by the broker Citi, with a price target of $0.58. That suggests a potential rise of the share price of just over 25% in the next year, if the broker is right.

Citi notes the recovery that Bubs is seeing, particularly when it comes to the daigou channel. The broker also thinks that the ASX share can also expand its addressable market.

Bubs gave investors an insight into potential performance in 2022 with its FY22 first quarter update. Total gross revenue nearly doubled to $18.5 million, whilst Bubs infant formula daigou sales increased 648% year on year.

The ASX share is also making progress internationally. For the first three months of FY22, international (excluding China) gross revenue increased 489% year on year, contributing 24% of quarterly sales. Export sales of Bubs infant formula to markets outside of China grew 154%.

Bubs has signalled its expanding global strategy by establishing entities in New Zealand, China and the USA.

Looking at the product categories, the infant nutrition portfolio – which has higher margins than the adult goat dairy portfolio – saw growth of 89%. The infant formula gross revenue grew 124% year on year and 64% quarter on quarter.

Bubs management say that they are confident on its vision to take Bubs to a global stage.

ELMO Software Ltd (ASX: ELO)

ELMO Software is a leading HR and payroll tech company. It has a substantial presence in both Australia and the UK.

It's currently rated as a buy by the broker Morgan Stanley with a price target of $7.80. This would be a rise of more than 50%, if the broker's prediction ends up being right.

ELMO Software is steadily adding more modules for its small and medium clients to utilise. This can increase revenue made from the client, and make the ELMO software even more valuable to the client (and make them more 'sticky').

The broker thinks the ASX share can benefit from a number of tailwinds, such as more companies utilising digital tools and software.

In the first three months of FY22, revenue increased 52% to $20.7 million and annualised recurring revenue (ARR) surged 61% to $88.5 million. Cash receipts went up 78% to $27.7 million whilst the business had $75.7 million of cash on hand. The company becoming cashflow neutral/positive could help investor thoughts on the business, according to the broker.

Extending ELMO's module suite, it recently launched 'Experiences' for improve employee engagement and 'COVIDsecure' for things like recording, monitoring and reporting COVID vaccination and test status.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Elmo Software. The Motley Fool Australia owns and has recommended Elmo Software. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

Brokers have been looking at these shares this week. Are they bullish?

Read more »

Coal miner holding a giant coal rock in his hand and making a circle with his other hand.
Broker Notes

What is this broker saying about New Hope Group shares?

Here's Bell Potter's guidance following earnings results.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Broker Notes

3 ASX 200 shares at 52-week lows: Buy, hold, or sell?

These ASX 200 shares have experienced significant falls over the past 12 months. Is there value here?

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Broker Notes

Buy, hold, sell: BHP, CSL, and Woodside shares

Let's see if analysts are bullish or bearish on these giants.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Why this beaten down $9 billion ASX 200 share is now a buy

A leading expert believes AI will help, rather than hinder, this tech focused ASX 200 stock.

Read more »